1188P - Clinical and immune effects patients with progressive disease treated with low dose of anti-CTLA-4, bortezomib, gemcitabine, naproxen and meloxicam
| Autor: | Marquez-Manriquez, J.P., Briseno, J.A.M., Quayle, K., Fernandez, L.M., Barajas, I.R., Torres-Montano, G., Durazo-Bustamante, F.A., Durazo-Acuna, A., Rangel-Reyna, L-A., Lopez-Hernandez, D., Rodriguez-Jasso, A., Trujillo-Acosta, M-A., Ramos-Garcia, E., Icedo-Zamora, S., Diaz, P.A.L. |
|---|---|
| Zdroj: | In Annals of Oncology September 2017 28 Supplement 5:v421-v421 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|